CD317 (BST2, PDCA-1) Monoclonal Antibody (eBio927), APC, eBioscience™, Invitrogen™

Description

• The eBio927 MAb reacts with PDCA-1 (BST2, CD317), a specific marker of plasmacytoid dendritic cells (pDC), also known as type I IFN-producing cells (IPC) in the naive mouse
• Mouse IPCs are typically CD11c+, CD11b-, B220+, Ly-6C+, and CD62L+
• PDCA-1 is predominantly expressed by IPCs in the naive mouse which represents a very minor population (<0.5%) of splenocytes
• It is upregulated on numerous cell types following stimulation which triggers an IFN response
• PDCA-1 cycles between cell surface and intracellular compartments and may function to regulate trafficking of secreted cytokines
• PDCA-1 (BST2) is the protein recognized by antibody 120G8
• The eBio927 MAb has also been shown to have functional activity
• The epitope recognized by eBio927 is distinct from eBio129c; thus, the antibodies can be used to costain, purify and identify pDCs
• BST2 (CD317, HM1.24 antigen, DAMP-2, tetherin) is an integral membrane protein that is involved in the development and growth of B-cells
• The surface expression of BST2 on fibroblast cell lines facilitated the stromal cell-dependent growth of DW34, a pre-B-cell line
• BST2 is highly expressed during B-cell development, from pro-B precursors to plasma cells, T-cells, monocytes, NK cells and DCs (at protein level), and myeloma cells
• Research studies have shown that BST2 also functions as an inhibitor of retrovirus release from human cells whose activity is antagonized by the HIV-1 accessory protein, Vpu
• While BST2 causes retention of virions on cell surfaces or endocytosis into BST2-positive compartments, its depletion abolished the viral requirement for Vpu for virus release, an activity that may represent a potential therapeutic strategy for the treatment of HIV/AIDS
• Another disease associated with BST2 dysfunction is stomatitis.